NCT07300891尚未招募2 期
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 72
- 主要终点
- ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab
研究概览
简要总结
This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score ≥ 0.857, who have not been previously exposed to immunotherapy.
All patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tissue slide collected within 2 years from the first dose of study drug must be provided.
This study will include a Screening Period, a Treatment Period, and a Follow-Up Period. All patients will complete up to 28 days of screening. During the Treatment Period, patients will receive tislelizumab 200 mg fixed dose once every 3 weeks by intravenous (IV) administration until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
After treatment discontinuation, patients will be follow-up for disease progression and survival status until death, withdrawal of consent, or study closure, whichever occurs first.
The end of study will be the timepoint when the final data for the study were collected. Additionally, the Investigator Sponsor has the right to terminate this study at any time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥ 20 years at the time of informed consent.
- •Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.
- •Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.
- •ECOG Performance Status Score 0 or
- •Patients with a life expectancy of at least 3 months.
- •Patients with adequate hematological and biological function as indicated by the following screening laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1.5×109/L
- •Platelets ≥ 75×109/L
- •Hemoglobin ≥ 9g/dL or ≥ 5.6 mmol/L (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)
- •Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL/min by Cockcroft-Gault formula
- •Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be < 3×ULN for patients with Gilbert's syndrome)
- •Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases
排除标准
- •Patients aged ≥ 20 years at the time of informed consent.
- •Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.
- •Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.
- •ECOG Performance Status Score 0 or
- •Patients with a life expectancy of at least 3 months.
- •Patients with adequate hematological and biological function as indicated by the following screening laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1.5×109/L
- •Platelets ≥ 75×109/L
- •Hemoglobin ≥ 9g/dL or ≥ 5.6 mmol/L (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)
- •Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL/min by Cockcroft-Gault formula
- •Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be < 3×ULN for patients with Gilbert's syndrome)
- •Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases
- •Key exclusion criteria Patients who meet any of the following criteria at the time of assessment will be excluded.
- •Patients with solid tumors from multiple primary origin (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years).
- •Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.
- •Patients are expected to require any other form of systemic or localized antineoplastic therapy while on trial (including radiation therapy, and/or surgical resection).
- •Patients who have previously received treatment with PD-1/PD-L1 inhibitor or CTLA-4 inhibitor e.g. pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, tislelizumab, dostarlimab, spartalizumab tremelimumab or ipilimumab
- •Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for ≥ 4 weeks before first dose of study drug.
- •Patients have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study in terms of efficacy and safety, interfere with the subject's participation for the full duration of the trial, or are not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Women who are pregnant or breastfeeding, or possibly pregnant.
- •Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before first dose of study drug.
研究组 & 干预措施
Tislelizumab(BGB-A317)
Experimental
干预措施: Tisleizumab(BGB-A317) (Drug)
结局指标
主要结局
ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab
时间窗: From enrollment to the end of treatment at 30days(+/-7)
ORR is defined as the proportion of patients who had complete response (CR) or partial response (PR) assessed by investigator using RECIST v1.1
ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab
时间窗: From enrollment to the end of treatment at 30days(+/-7)
ORR is defined as the proportion of patients who had complete response (CR) or partial response (PR) assessed by investigator using RECIST v1.1
次要结局
- iORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iPFS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iCBR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iDOR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- The safety of Tislelizumab in refractory solid tumor patients per NCI CTCAE v5.0(From enrollment to the end of treatment at 30days(+/-7))
- ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.955 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 1.058 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- OS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- PFS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- CBR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- DOR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.955 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- ORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 1.058 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- OS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- PFS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- CBR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- DOR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iORR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iPFS in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iCBR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- iDOR in refractory solid tumor patients with T cell inflamed GEP score ≥ 0.857 treated with Tislelizumab.(From enrollment to the end of treatment at 30days(+/-7))
- The safety of Tislelizumab in refractory solid tumor patients per NCI CTCAE v5.0(From enrollment to the end of treatment at 30days(+/-7))
研究者
Se-Hoon Lee
Principal Investigator
Samsung Medical Center
相似试验
招募中
2 期
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023-503812-34-00Seagen Inc.79
招募中
2 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patients2024-513032-14-00Adaptimmune LLC, Adaptimmune LLC21
进行中（未招募）
2 期
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203Iovance Biotherapeutics, Inc.100
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
招募中
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma2023-503418-63-00Beigene Ltd.28